• Oncology
  • Current

The concept of synthetic lethality is that while a tumor can tolerate individual defects in its DNA, specific combinations of these defects could lead to tumor cell death. This concept has been recently validated in the clinic with the approvals of several PARP inhibitors for BRCA-mutant cancers. Repare Therapeutics is focused on the discovery and development of novel synthetic lethal cancer therapies, using a proprietary CRISPR-enabled drug discovery platform.